Last updated 16 days ago
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
812 patients around the world
Available in Brazil, Colombia, Argentina, Mexico, United States
Hoffmann-La Roche
32Research sites
812Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Recruiting
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
Recruiting
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
Consultorios Médicos Dr. Isaac Scherbovsky - Mendoza
Recruiting
Fundación CENIT para la Investigación en Neurociencias
Recruiting
Centro Oncológico Korben
Recruiting
Instituto de Oncología de Rosario - IOR
Recruiting
ONCOSITE - Centro de Pesquisa Clinica em Oncologia
Recruiting
Hospital de Câncer de Barretos - Fundação PIO XII
Recruiting
Pronutrir Nutrição
Recruiting
StudyheredERA
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05296798
